Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Fall;13(3):308-16.
doi: 10.1111/j.1527-3458.2007.00021.x.

CGP7930: a positive allosteric modulator of the GABAB receptor

Affiliations
Review

CGP7930: a positive allosteric modulator of the GABAB receptor

C L Adams et al. CNS Drug Rev. 2007 Fall.

Abstract

CGP7930 (3-(3',5'-Di-tert-butyl-4'-hydroxy)phenyl-2,2-dimethylpropanol) is a positive allosteric modulator of the metabotropic GABAB receptor. CGP7930 has been found to modulate the GABAB receptor in the open, or high affinity, state increasing agonist affinity for the receptor and signal transduction efficacy following agonist stimulation. The GABAB heteromeric subunit B2, involved in signal transduction but not ligand binding, seems to be the site of action of CGP7930 and similar allosteric modulators. When administered alone in naïve animals, CGP7930 acts as an anxiolytic in rodents without other overt behavioral effects and has also been demonstrated to reduce self-administration of nicotine, cocaine, or alcohol in rodents, suggesting that "fine tuning" of the GABAB receptor by positive allosteric modulators may be able to regulate abuse of these drugs. Baclofen, the GABAB agonist, is currently finding use in treating addiction and various other disorders, but this can result in off-target effects and tolerance. CGP7930 when co-administered with baclofen enhances its potency, which could in theory minimize deleterious effects. Further study of CGP7930 is required, but this compound, and others like it, holds potential in a clinical setting.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The chemical structure of CGP7930.

References

    1. Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, Agabio R, Colombo G, Gessa GL, Gasbarrini G (2002) Baclofen efficacy in reducing alcohol craving and intake: A preliminary double‐blind randomized controlled study. Alcohol Alcohol 37:504‐508. - PubMed
    1. Addolorato G, Leggio L, Abenavoli L, Agabio R, Caputo F, Capristo E, Colombo G, Gessa GL, Gasbarrini G (2006) Baclofen in the treatment of alcohol withdrawal syndrome: A comparative study vs diazepam. Am J Med 119:13‐18. - PubMed
    1. Arias Montano JA, Martinez‐Fong D, Aceves J (1992) GABAB receptor activation partially inhibits N‐methyl‐D‐aspartate‐mediated tyrosine hydroxylase stimulation in rat striatal slices. Eur J Pharmacol 218:335‐338. - PubMed
    1. Asay MJ, Boyd SK (2006) Characterization of the binding of [3H]CGP54626 to GABAB receptors in the male bullfrog (Rana catesbeiana). Brain Res 1094:76‐85. - PubMed
    1. Bettler B, Tiao JY (2006) Molecular diversity, trafficking and subcellular localization of GABAB receptors. Pharmacol Ther 110:533‐543. - PubMed

Substances

LinkOut - more resources